News | Radiation Therapy | September 22, 2016

Mevion to Spotlight Adaptive Intensity Modulated Proton Therapy at ASTRO 2016

Company will introduce Hyperscan with new adaptive aperture technology allowing faster, sharper and robust pencil beam scanning

Mevion, Hyperscan with Adaptive Aperture, intensity modualted proton therapy, IMPT, ASTRO 2016

September 22, 2016 — Mevion Medical Systems will showcase its pencil beam scanning Hyperscan with Adaptive Aperture at the 2016 American Society for Radiation Oncology (ASTRO) Annual Meeting, Sept. 25-28 in Boston. The advanced proton micro-multileaf collimator (mMLC) technology is integrated into the Mevion S250i with Hyperscan, making pencil beam scanning sharper and faster and delivering robust intensity modulated proton therapy (IMPT).

Hyperscan with Adaptive Aperture delivers a pencil beam that is up to 50 times faster and 3 times sharper than conventional systems used for IMPT, and can scan a typical lung tumor in less than two seconds. The technology includes a low-profile mMLC system designed specifically for pencil beam scanning that is capable of delivering the sharpest penumbra physically achievable with protons without the need for manual apertures and adjustments, according to Mevion. Its novel layer-by-layer specific beam collimation and blocking achieves 1-3mm collimated spot sizes, for all energies, at any depth.

James Cooley, senior accelerator engineer at Mevion said the new technology is ideal for treating pediatric tumors or shallow brain tumors where small spot sizes have been difficult to achieve by conventional systems.

Mevion is also announcing the growth of its leadership team. The expansion includes the hiring of three industry experts and two internal moves:

  • Yoel Bakas, vice president of sales, Americas, joins Mevion from Varian Medical Systems, where he oversaw strategic account development and has focused on medical devices sales for the past 17 years;
  • Scott Soehl, vice president of international sales, joins Mevion with more than 35 years of radiation oncology experience, having previously worked at Elekta and IMPAC Medical Systems;
  • Curt Kienast, vice president of global services, is promoted from within Mevion where he previously served as senior director of product development. Curt has more than 15 years of experience in healthcare quality and services;
  • Chris Dodge, field vice president, The Americas; business development & customer financing, joins Mevion with 30 years of medical device sales and marketing experience, having previously worked at Varian Medical Systems for the past 15 years; and
  • George Rugg, vice president of business development, is appointed from his previous position as Mevion’s vice president of global services. George’s career spans 30 years of working in the oncology field.

For more information: www.mevion.com

Related Content

Merit Medical Completes Acquisition of Cianna Medical
News | Women's Health | November 14, 2018
Disposable device manufacturer Merit Medical Systems Inc. announced the closing of a definitive merger agreement to...
Videos | ASTRO | November 08, 2018
ITN Editor Dave Fornell took a tour of some of the most innovative technologies on display on the expo floor at the 
The Fujifilm FCT Embrace CT System displayed for the first time at ASTRO 2018.
360 Photos | 360 View Photos | November 07, 2018
Fujifilm's first FDA-cleared compu...
This is the Siemens Magnetom Sola RT edition 1.5T MRI system optimized for radiation therapy displayed for the first time since gaining FDA clearance in 2018. It was displayed at the American Society for Radiotherapy and Oncology (ASTRO) 2018 annual meeting. Read more about this system at ASTRO 2018. #ASTRO18 #ASTRO2018
360 Photos | 360 View Photos | November 07, 2018
This is the Siemens Magnetom Sola RT edition 1.5T MRI system optimized for...
GE Healthcare Discovery RF Gen 2 system displayed at ASTRO 2018. It is a dedicated computed tomography (CT) scanner for radiation oncology
360 Photos | 360 View Photos | November 07, 2018
This is the GE Healthcare Discovery RF Gen 2 system displayed at the ...
Proton Therapy for Pediatric Brain Tumors Has Favorable Cognitive Outcomes
News | Proton Therapy | November 06, 2018
Proton therapy treatment for pediatric brain tumor patients is associated with better neurocognitive outcomes compared...
The patient’s wife changes the Optune array. Clinical trials indicate that the electrical fields emitted by Optune have the potential to lengthen the lives of patients with glioblastoma.

The patient’s wife changes the Optune array. Clinical trials indicate that the electrical fields emitted by Optune have the potential to lengthen the lives of patients with glioblastoma.

Feature | Radiation Oncology | November 06, 2018 | By Greg Freiherr
Approximately 11,000 professionals attended the four-day meeting of the...